Citi Upgrades Harley-Davidson to Buy, Sees 34% Upside to $33
Citi points to steadier U.S. demand, cost reductions, and a major 2027 product launch as key catalysts.
Already have an account? Sign in.
Citi points to steadier U.S. demand, cost reductions, and a major 2027 product launch as key catalysts.
Alector grants Genentech exclusive rights to AL050, a brain-penetrant GCase enzyme therapy for Parkinson’s, for $100 million upfront and up to $1.17 billion more.
BofA upgraded DraftKings to Buy with a $27 target, about 45% above the last close, citing less cannibalization and bottoming estimates.
C.H. Robinson is buying RXO for about $5.8 billion to add density, cut costs, and widen its lead in a fragmented freight brokerage market.